Golam M Khandaker1, Rebecca M Pearson2, Stanley Zammit3, Glyn Lewis4, Peter B Jones1. 1. Department of Psychiatry, University of Cambridge, Cambridge, England2National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, England3Collaboration for Leadership in Applied Health Research and Care, East of England, Cambri. 2. Centre for Mental Health, Addiction and Suicide Research, School of Social and Community Medicine, University of Bristol, Bristol, England. 3. Centre for Mental Health, Addiction and Suicide Research, School of Social and Community Medicine, University of Bristol, Bristol, England6Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric. 4. Centre for Mental Health, Addiction and Suicide Research, School of Social and Community Medicine, University of Bristol, Bristol, England7Division of Psychiatry, University College London, London, England.
Abstract
IMPORTANCE: Longitudinal studies have linked the systemic inflammatory markers interleukin 6 (IL-6) and C-reactive protein (CRP) with the risk of developing heart disease and diabetes mellitus, which are common comorbidities for depression and psychosis. Recent meta-analyses of cross-sectional studies have reported increased serum levels of these inflammatory markers in depression, first-episode psychosis, and acute psychotic relapse; however, the direction of the association has been unclear. OBJECTIVE: To test the hypothesis that higher serum levels of IL-6 and CRP in childhood would increase future risks for depression and psychosis. DESIGN, SETTING, AND PARTICIPANTS: The Avon Longitudinal Study of Parents and Children (ALSPAC)is a prospective general population birth cohort study based in Avon County, England. We have studied a subsample of approximately 4500 individuals from the cohort with data on childhood IL-6 and CRP levels and later psychiatric assessments. MEASUREMENT OF EXPOSURE: Levels of IL-6 and CRP were measured in nonfasting blood samples obtained in participants at age 9 years. MAIN OUTCOMES AND MEASURES: Participants were assessed at age 18 years. Depression was measured using the Clinical Interview Schedule-Revised (CIS-R) and Mood and Feelings Questionnaire (MFQ), thus allowing internal replication; psychotic experiences (PEs) and psychotic disorder were measured by a semistructured interview. RESULTS: After adjusting for sex, age, body mass index, ethnicity, social class, past psychological and behavioral problems, and maternal postpartum depression, participants in the top third of IL-6 values compared with the bottom third at age 9 years were more likely to be depressed (CIS-R) at age 18 years (adjusted odds ratio [OR], 1.55; 95% CI, 1.13-2.14). Results using the MFQ were similar. Risks of PEs and of psychotic disorder at age 18 years were also increased with higher IL-6 levels at baseline (adjusted OR, 1.81; 95% CI, 1.01-3.28; and adjusted OR, 2.40; 95% CI, 0.88-6.22, respectively). Higher IL-6 levels in childhood were associated with subsequent risks of depression and PEs in a dose-dependent manner. CONCLUSIONS AND RELEVANCE: Higher levels of the systemic inflammatory marker IL-6 in childhood are associated with an increased risk of developing depression and psychosis in young adulthood. Inflammatory pathways may provide important new intervention and prevention targets for these disorders. Inflammation might explain the high comorbidity between heart disease, diabetes mellitus, depression, and schizophrenia.
IMPORTANCE: Longitudinal studies have linked the systemic inflammatory markers interleukin 6 (IL-6) and C-reactive protein (CRP) with the risk of developing heart disease and diabetes mellitus, which are common comorbidities for depression and psychosis. Recent meta-analyses of cross-sectional studies have reported increased serum levels of these inflammatory markers in depression, first-episode psychosis, and acute psychotic relapse; however, the direction of the association has been unclear. OBJECTIVE: To test the hypothesis that higher serum levels of IL-6 and CRP in childhood would increase future risks for depression and psychosis. DESIGN, SETTING, AND PARTICIPANTS: The Avon Longitudinal Study of Parents and Children (ALSPAC)is a prospective general population birth cohort study based in Avon County, England. We have studied a subsample of approximately 4500 individuals from the cohort with data on childhood IL-6 and CRP levels and later psychiatric assessments. MEASUREMENT OF EXPOSURE: Levels of IL-6 and CRP were measured in nonfasting blood samples obtained in participants at age 9 years. MAIN OUTCOMES AND MEASURES: Participants were assessed at age 18 years. Depression was measured using the Clinical Interview Schedule-Revised (CIS-R) and Mood and Feelings Questionnaire (MFQ), thus allowing internal replication; psychotic experiences (PEs) and psychotic disorder were measured by a semistructured interview. RESULTS: After adjusting for sex, age, body mass index, ethnicity, social class, past psychological and behavioral problems, and maternal postpartum depression, participants in the top third of IL-6 values compared with the bottom third at age 9 years were more likely to be depressed (CIS-R) at age 18 years (adjusted odds ratio [OR], 1.55; 95% CI, 1.13-2.14). Results using the MFQ were similar. Risks of PEs and of psychotic disorder at age 18 years were also increased with higher IL-6 levels at baseline (adjusted OR, 1.81; 95% CI, 1.01-3.28; and adjusted OR, 2.40; 95% CI, 0.88-6.22, respectively). Higher IL-6 levels in childhood were associated with subsequent risks of depression and PEs in a dose-dependent manner. CONCLUSIONS AND RELEVANCE: Higher levels of the systemic inflammatory marker IL-6 in childhood are associated with an increased risk of developing depression and psychosis in young adulthood. Inflammatory pathways may provide important new intervention and prevention targets for these disorders. Inflammation might explain the high comorbidity between heart disease, diabetes mellitus, depression, and schizophrenia.
Authors: Imran B Chaudhry; Jaime Hallak; Nusrat Husain; Fareed Minhas; John Stirling; Paul Richardson; Serdar Dursun; Graham Dunn; Bill Deakin Journal: J Psychopharmacol Date: 2012-04-23 Impact factor: 4.153
Authors: Robert Dantzer; Jason C O'Connor; Gregory G Freund; Rodney W Johnson; Keith W Kelley Journal: Nat Rev Neurosci Date: 2008-01 Impact factor: 34.870
Authors: D Gimeno; M Kivimäki; E J Brunner; M Elovainio; R De Vogli; A Steptoe; M Kumari; G D O Lowe; A Rumley; M G Marmot; J E Ferrie Journal: Psychol Med Date: 2008-06-04 Impact factor: 7.723
Authors: Karen A Matthews; Laura L Schott; Joyce T Bromberger; Jill M Cyranowski; Susan A Everson-Rose; MaryFran Sowers Journal: Brain Behav Immun Date: 2009-08-14 Impact factor: 7.217
Authors: Ole Köhler-Forsberg; Liselotte Petersen; Christiane Gasse; Preben B Mortensen; Soren Dalsgaard; Robert H Yolken; Ole Mors; Michael E Benros Journal: JAMA Psychiatry Date: 2019-03-01 Impact factor: 21.596
Authors: Christopher A Lowry; David G Smith; Philip H Siebler; Dominic Schmidt; Christopher E Stamper; James E Hassell; Paula S Yamashita; James H Fox; Stefan O Reber; Lisa A Brenner; Andrew J Hoisington; Teodor T Postolache; Kerry A Kinney; Dante Marciani; Mark Hernandez; Sian M J Hemmings; Stefanie Malan-Muller; Kenneth P Wright; Rob Knight; Charles L Raison; Graham A W Rook Journal: Curr Environ Health Rep Date: 2016-09
Authors: Heather M Derry; Avelina C Padin; Jennifer L Kuo; Spenser Hughes; Janice K Kiecolt-Glaser Journal: Curr Psychiatry Rep Date: 2015-10 Impact factor: 5.285